IRADIMED CORPORATION (IRMD) Q3 2025 Earnings Call Transcript
Revenue $21.2 million in Q3 2025, a 16% increase from $18.3 million in Q3 2024. Growth driven by strong performance across product lines, particularly MRI compatible IV infusion pump systems and patient vital signs monitoring systems.
Gross Profit $16.4 million in Q3 2025, up 16% from $14.1 million in Q3 2024. Gross margin was 78%, compared to 77% in Q3 2024. Improvement attributed to strong margin performance despite moving manufacturing operations to a new facility.
Operating Expenses $9.7 million in Q3 2025, up 15% from $8.4 million in Q3 2024. Increase driven by higher sales and marketing expenses, modest increases in general and administrative costs, and research and development expenses.
Income from Operations $6.8 million in Q3 2025, a 17% increase from $5.8 million in Q3 2024. Growth attributed to higher revenue and controlled cost of goods sold.
Net Income $5.6 million or $0.43 per diluted share in Q3 2025, a 12% increase from $5 million or $0.40 per diluted share in Q3 2024. Non-GAAP net income was $6.1 million or $0.47 per diluted share, up 9% from $0.43.
Cash and Cash Equivalents $56.5 million at the end of Q3 2025, up from $52.2 million at year-end 2024. Increase driven by strong cash flow from operations.
Cash Flow from Operations $7 million for Q3 2025 and $19 million year-to-date. Free cash flow was $5.7 million for the quarter and $11 million year-to-date, reflecting capital expenditures of $8 million year-to-date.
MRI Compatible IV Infusion Pump Systems Revenue $8.3 million in Q3 2025, up 20% year-over-year. Growth driven by increased shipments and replacement orders for older pumps.
Patient Vital Signs Monitoring Systems Revenue $6.9 million in Q3 2025, up 16% year-over-year. Growth attributed to successful emphasis on monitoring sales.
Disposable Revenue $4.1 million in Q3 2025, a 12% increase year-over-year. Growth reflects increased utilization of devices.
Domestic Sales $18.1 million in Q3 2025, a 19% increase year-over-year. Domestic revenue accounted for 85% of total revenue, up from 83% in Q3 2024.
International Sales $3.1 million in Q3 2025, consistent with Q3 2024.
Trade with 70% Backtested Accuracy
Analyst Views on IRMD
About IRMD
About the author
Transcript of IRadimed (IRMD) Earnings Call for Q3 2025
- Author's Perspective: The views and opinions presented are solely those of the author.
- No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
Upcoming Ex-Dividend Dates for Duke Energy, American States Water, and iRadimed
Upcoming Ex-Dividend Dates: Duke Energy Corp (DUK), American States Water Co (AWR), and iRadimed Corp (IRMD) will trade ex-dividend on 11/14/25, 12/2/25, and 11/25/25 respectively, with dividends of $1.065, $0.504, and $0.17.
Expected Price Adjustments: Following the ex-dividend dates, shares of DUK, AWR, and IRMD are expected to open lower by approximately 0.86%, 0.66%, and 0.20% respectively.
Dividend Yield Estimates: The estimated annualized yields for the upcoming dividends are 3.44% for Duke Energy, 2.66% for American States Water, and 0.80% for iRadimed, reflecting their historical dividend stability.
Current Trading Performance: As of Wednesday trading, Duke Energy shares are up 0.6%, American States Water shares are up 1.1%, while iRadimed shares are down 1.7%.
IRADIMED CORPORATION Recognized in TIME's 2026 List of America's Growth Leaders
Recognition: Iradimed Corporation has been named one of America's Growth Leaders for 2026 by TIME, ranking 79th among 501 companies recognized for outstanding growth based on revenue, financial stability, and stock performance.
Company Performance: The company has achieved 17 consecutive quarters of record revenue, reflecting its commitment to innovation and operational excellence in the MRI-compatible medical device market.
Innovative Products: Iradimed is known for its MRidium® MRI-compatible IV infusion pump and the 3880 MRI-compatible patient vital signs monitoring system, both designed to operate safely in MRI environments, enhancing patient care during procedures.
Methodology: The ranking was determined through a rigorous evaluation by TIME and Statista, focusing on revenue growth, financial stability, and stock performance, with a maximum score of 100 points awarded to the top companies.
Experts Predict FHLC Will Hit $81
Fidelity MSCI Health Care Index ETF Analysis: The Fidelity MSCI Health Care Index ETF (FHLC) has an implied analyst target price of $81.28, indicating a potential upside of 15.88% from its current trading price of $70.14.
Notable Holdings with Upside Potential: Key underlying holdings of FHLC, such as Xeris Biopharma Holdings (XERS), Mineralys Therapeutics (MLYS), and iRadimed Corp (IRMD), show significant upside potential based on analyst target prices, with XERS at 38.16% higher, MLYS at 21.59%, and IRMD at 17.06%.
Analyst Target Price Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets relative to current prices could lead to potential downgrades if they are based on outdated information.
Investor Research Recommendation: Investors are encouraged to conduct further research to assess the validity of analysts' targets in light of recent developments in the companies and the healthcare industry.
Daily Upgrade Report for Validea Motley Fool Strategy - November 4, 2025
Validea's Small-Cap Growth Investor Model: The model, based on Motley Fool's strategy, identifies small-cap growth stocks with strong fundamentals and price performance, highlighting LOEWS CORP and IRADIMED CORP as notable stocks with improved ratings.
LOEWS CORP Overview: Loews Corporation, a large-cap value stock in the insurance industry, saw its rating increase from 65% to 72%, indicating solid fundamentals and valuation, with a focus on its diverse segments including insurance, pipelines, and hotels.
IRADIMED CORP Overview: IRadimed Corporation, a small-cap growth stock in the medical equipment sector, improved its rating from 67% to 80%, reflecting strong fundamentals and valuation, particularly for its MRI-compatible medical devices.
About Motley Fool and Validea: Motley Fool, founded by the Gardner brothers, provides investment insights and commentary, while Validea offers research based on the strategies of renowned investors, aiming to help investors outperform the market.
Iradimed Corp Sees Profit Increase in Q2
Earnings Performance: Iradimed Corp reported second-quarter earnings of $5.57 million, or $0.43 per share, an increase from $5.05 million, or $0.40 per share, in the previous year.
Adjusted Earnings: The company’s adjusted earnings for the quarter were $6.10 million, or $0.47 per share, excluding certain items.
Revenue Growth: Revenue rose by 15.7% to $21.20 million compared to $18.32 million in the same quarter last year.
Future Guidance: For the next quarter, Iradimed expects EPS between $0.43 and $0.47 and revenue between $21.4 million and $22.4 million, with full-year EPS guidance of $1.68 to $1.72 and revenue of $82.5 to $83.5 million.
Transcript of IRadimed (IRMD) Earnings Call for Q3 2025
- Author's Perspective: The views and opinions presented are solely those of the author.
- No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
Upcoming Ex-Dividend Dates for Duke Energy, American States Water, and iRadimed
Upcoming Ex-Dividend Dates: Duke Energy Corp (DUK), American States Water Co (AWR), and iRadimed Corp (IRMD) will trade ex-dividend on 11/14/25, 12/2/25, and 11/25/25 respectively, with dividends of $1.065, $0.504, and $0.17.
Expected Price Adjustments: Following the ex-dividend dates, shares of DUK, AWR, and IRMD are expected to open lower by approximately 0.86%, 0.66%, and 0.20% respectively.
Dividend Yield Estimates: The estimated annualized yields for the upcoming dividends are 3.44% for Duke Energy, 2.66% for American States Water, and 0.80% for iRadimed, reflecting their historical dividend stability.
Current Trading Performance: As of Wednesday trading, Duke Energy shares are up 0.6%, American States Water shares are up 1.1%, while iRadimed shares are down 1.7%.
IRADIMED CORPORATION Recognized in TIME's 2026 List of America's Growth Leaders
Recognition: Iradimed Corporation has been named one of America's Growth Leaders for 2026 by TIME, ranking 79th among 501 companies recognized for outstanding growth based on revenue, financial stability, and stock performance.
Company Performance: The company has achieved 17 consecutive quarters of record revenue, reflecting its commitment to innovation and operational excellence in the MRI-compatible medical device market.
Innovative Products: Iradimed is known for its MRidium® MRI-compatible IV infusion pump and the 3880 MRI-compatible patient vital signs monitoring system, both designed to operate safely in MRI environments, enhancing patient care during procedures.
Methodology: The ranking was determined through a rigorous evaluation by TIME and Statista, focusing on revenue growth, financial stability, and stock performance, with a maximum score of 100 points awarded to the top companies.
Experts Predict FHLC Will Hit $81
Fidelity MSCI Health Care Index ETF Analysis: The Fidelity MSCI Health Care Index ETF (FHLC) has an implied analyst target price of $81.28, indicating a potential upside of 15.88% from its current trading price of $70.14.
Notable Holdings with Upside Potential: Key underlying holdings of FHLC, such as Xeris Biopharma Holdings (XERS), Mineralys Therapeutics (MLYS), and iRadimed Corp (IRMD), show significant upside potential based on analyst target prices, with XERS at 38.16% higher, MLYS at 21.59%, and IRMD at 17.06%.
Analyst Target Price Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets relative to current prices could lead to potential downgrades if they are based on outdated information.
Investor Research Recommendation: Investors are encouraged to conduct further research to assess the validity of analysts' targets in light of recent developments in the companies and the healthcare industry.
Daily Upgrade Report for Validea Motley Fool Strategy - November 4, 2025
Validea's Small-Cap Growth Investor Model: The model, based on Motley Fool's strategy, identifies small-cap growth stocks with strong fundamentals and price performance, highlighting LOEWS CORP and IRADIMED CORP as notable stocks with improved ratings.
LOEWS CORP Overview: Loews Corporation, a large-cap value stock in the insurance industry, saw its rating increase from 65% to 72%, indicating solid fundamentals and valuation, with a focus on its diverse segments including insurance, pipelines, and hotels.
IRADIMED CORP Overview: IRadimed Corporation, a small-cap growth stock in the medical equipment sector, improved its rating from 67% to 80%, reflecting strong fundamentals and valuation, particularly for its MRI-compatible medical devices.
About Motley Fool and Validea: Motley Fool, founded by the Gardner brothers, provides investment insights and commentary, while Validea offers research based on the strategies of renowned investors, aiming to help investors outperform the market.
Iradimed Corp Sees Profit Increase in Q2
Earnings Performance: Iradimed Corp reported second-quarter earnings of $5.57 million, or $0.43 per share, an increase from $5.05 million, or $0.40 per share, in the previous year.
Adjusted Earnings: The company’s adjusted earnings for the quarter were $6.10 million, or $0.47 per share, excluding certain items.
Revenue Growth: Revenue rose by 15.7% to $21.20 million compared to $18.32 million in the same quarter last year.
Future Guidance: For the next quarter, Iradimed expects EPS between $0.43 and $0.47 and revenue between $21.4 million and $22.4 million, with full-year EPS guidance of $1.68 to $1.72 and revenue of $82.5 to $83.5 million.
